quarta-feira, outubro 26, 2005
Tipranavir aprovado na Europa
Veremos quanto tempo o INFARMED demorará para emitir a Autorização de Introducção no Mercado (A.I.M.) em Portugal.
E o preço que a Boehringer pedirá...
Boehringer-Ingelheim receives EU approval for HIV drug Aptivus
10.26.2005, 07:28 AM
INGELHEIM, Germany (AFX) - Boehringer-Ingelheim GmbH said it has received approval from the European Commission to market its HIV drug Aptivus (tipravanir) for treatment of HIV in combination with other anti-retroviral agents.
Aptivus specifically helps patients who have become resistant to current treatment options.Boehringer said authorisation was based on 'exceptional circumstances' given that HIV/AIDS is a life threatening illness with a need for rapid access to new treatment options.
Aptivus has so far this year been approved in the US, Mexico and Switzerland, and is under review by further regulatory agencies.
Boehringer Ingelheim is among the world's 20 largest pharmaceutical companies. It had sales of 8.2 bln eur last year.
